Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
Pilot clinical trial - Phase 2a, multicenter, single arm, open label trial - to evaluate
efficacy and safety of concomitant combination treatment with Gemcitabine and Romidepsin
(GEMRO) regimen as salvage treatment in relapsed/refractory PTCL (peripheral T-cell lymphoma)
in a selected population of patients.